Should You Buy vTv Therapeutics Inc (VTVT) Today? Analysis, Price Targets, and 2026 Outlook.
Analysis Updated At
2026/01/26
vTv Therapeutics Inc (VTVT) is not a strong buy for a beginner investor with a long-term strategy at this moment. While the company has promising prospects for its lead drug candidate, the technical indicators, financial performance, and lack of immediate positive trading signals suggest waiting for more favorable conditions or clearer catalysts.
Technical Analysis
The MACD is negative and contracting, RSI is neutral at 41.489, and moving averages are converging, indicating no clear trend. The stock is trading below the pivot level of 36.339, with resistance at 40.216 and support at 32.462. The technical indicators suggest a neutral to slightly bearish trend.
Analyst Ratings and Price Target Trends
Analysts are optimistic, with recent buy ratings and price targets ranging from $40 to $67. They highlight the potential of cadisegliatin to address unmet needs in Type 1 diabetes and project significant peak sales. However, these projections are long-term and contingent on successful Phase 3 trial results.
Wall Street analysts forecast VTVT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for VTVT is 51.33 USD with a low forecast of 40 USD and a high forecast of 67 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
Wall Street analysts forecast VTVT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for VTVT is 51.33 USD with a low forecast of 40 USD and a high forecast of 67 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
Current: 34.040
Current: 34.040
